Nothing Special   »   [go: up one dir, main page]

CR9568A - DERIVADOS DE PIRIDO[2,3-d]PIRIMIDINA, SU PREPARACION, SU APLICACION EN TERAPEUTICA - Google Patents

DERIVADOS DE PIRIDO[2,3-d]PIRIMIDINA, SU PREPARACION, SU APLICACION EN TERAPEUTICA

Info

Publication number
CR9568A
CR9568A CR9568A CR9568A CR9568A CR 9568 A CR9568 A CR 9568A CR 9568 A CR9568 A CR 9568A CR 9568 A CR9568 A CR 9568A CR 9568 A CR9568 A CR 9568A
Authority
CR
Costa Rica
Prior art keywords
therapeutics
pyrimidine
derivatives
preparation
application
Prior art date
Application number
CR9568A
Other languages
English (en)
Inventor
Bernard Bourrie
Pierre Casellas
Samir Jegham
Claude Muneaux
Pierre Perreaut
Original Assignee
St Jude Medical Cardiolgoy Division Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by St Jude Medical Cardiolgoy Division Inc filed Critical St Jude Medical Cardiolgoy Division Inc
Publication of CR9568A publication Critical patent/CR9568A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invencion tiene como objetivo derivados de pirido[2,3-d]pirimidina, su preparacion y su aplicacion en terapeutica. Estos compuestos son potencialmente utiles para tratar trastornos de la proliferacion celular.
CR9568A 2005-07-01 2007-12-06 DERIVADOS DE PIRIDO[2,3-d]PIRIMIDINA, SU PREPARACION, SU APLICACION EN TERAPEUTICA CR9568A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0507032A FR2887882B1 (fr) 2005-07-01 2005-07-01 Derives de pyrido[2,3-d] pyrimidine, leur preparation, leur application en therapeutique

Publications (1)

Publication Number Publication Date
CR9568A true CR9568A (es) 2008-02-20

Family

ID=36096420

Family Applications (1)

Application Number Title Priority Date Filing Date
CR9568A CR9568A (es) 2005-07-01 2007-12-06 DERIVADOS DE PIRIDO[2,3-d]PIRIMIDINA, SU PREPARACION, SU APLICACION EN TERAPEUTICA

Country Status (41)

Country Link
US (2) US7504406B2 (es)
EP (2) EP1902054B1 (es)
JP (1) JP4472009B2 (es)
KR (1) KR101298344B1 (es)
CN (2) CN102260258B (es)
AR (1) AR054812A1 (es)
AT (1) ATE423119T1 (es)
AU (1) AU2006264801B2 (es)
BR (1) BRPI0613020A2 (es)
CA (1) CA2610794C (es)
CR (1) CR9568A (es)
CY (2) CY1110457T1 (es)
DE (1) DE602006005246D1 (es)
DK (2) DK1902054T3 (es)
DO (1) DOP2006000145A (es)
EA (1) EA014312B1 (es)
EC (1) ECSP078011A (es)
ES (2) ES2322101T3 (es)
FR (1) FR2887882B1 (es)
HK (1) HK1122797A1 (es)
HR (2) HRP20090236T1 (es)
IL (1) IL187900A0 (es)
JO (1) JO2550B1 (es)
MA (1) MA29561B1 (es)
ME (1) ME01813B (es)
MX (1) MX2007016239A (es)
MY (1) MY143089A (es)
NO (1) NO20080418L (es)
NZ (1) NZ564072A (es)
PA (1) PA8684801A1 (es)
PE (1) PE20070139A1 (es)
PL (2) PL1902054T3 (es)
PT (2) PT1902054E (es)
RS (2) RS53211B (es)
SI (2) SI2020410T1 (es)
TN (1) TNSN07440A1 (es)
TW (1) TWI321566B (es)
UA (1) UA92021C2 (es)
UY (1) UY29645A1 (es)
WO (1) WO2007003765A1 (es)
ZA (1) ZA200711032B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2873118B1 (fr) 2004-07-15 2007-11-23 Sanofi Synthelabo Derives de pyrido-pyrimidine, leur application en therapeutique
FR2887882B1 (fr) * 2005-07-01 2007-09-07 Sanofi Aventis Sa Derives de pyrido[2,3-d] pyrimidine, leur preparation, leur application en therapeutique
FR2896246B1 (fr) 2006-01-13 2008-08-15 Sanofi Aventis Sa Derives de pyrido-pyrimidone, leur preparation, leur application en therapeutique.
FR2910813B1 (fr) 2006-12-28 2009-02-06 Sanofi Aventis Sa Nouvelle utilisation therapeutique pour le traitement des leucemies
CA2739901A1 (en) 2008-10-17 2010-04-22 Akaal Pharma Pty Ltd S1p receptors modulators
EP2344484B1 (en) * 2008-10-17 2016-06-08 Akaal Pharma Pty Ltd S1p receptors modulators and use thereof
FR2948568B1 (fr) * 2009-07-30 2012-08-24 Sanofi Aventis Formulation pharmaceutique
CN103204827B (zh) * 2012-01-17 2014-12-03 上海科州药物研发有限公司 作为蛋白激酶抑制剂的苯并噻二唑化合物及其制备方法和用途
EP2638911A1 (en) 2012-03-14 2013-09-18 Sanofi Novel combinations for treating acute myeloid leukaemia or chronic myeloid leukaemia
CN103833771A (zh) * 2012-11-22 2014-06-04 天津滨江药物研发有限公司 作为蛋白激酶Mek抑制剂的苯并五元杂环化合物及其制备方法和用途

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1171218A (en) 1967-11-09 1969-11-19 Parke Davis & Co New Heterocyclic Amine Compounds and Methods for their Production
JPH04128276A (ja) 1990-09-19 1992-04-28 Pfizer Pharmaceut Co Ltd アミノベンゾサルタム誘導体およびその用途
IL115256A0 (en) 1994-11-14 1995-12-31 Warner Lambert Co 6-Aryl pyrido (2,3-d) pyrimidines and naphthyridines and their use
WO1996015128A2 (en) 1994-11-14 1996-05-23 Warner-Lambert Company 6-ARYL PYRIDO[2,3-d]PYRIMIDINES AND NAPHTHYRIDINES FOR INHIBITING PROTEIN TYROSINE KINASE MEDIATED CELLULAR PROLIFERATION
US5620981A (en) 1995-05-03 1997-04-15 Warner-Lambert Company Pyrido [2,3-D]pyrimidines for inhibiting protein tyrosine kinase mediated cellular proliferation
IL117923A (en) 1995-05-03 2000-06-01 Warner Lambert Co Anti-cancer pharmaceutical compositions containing polysubstituted pyrido¬2,3-d¾pyrimidine derivatives and certain such novel compounds
YU50402A (sh) * 2000-01-25 2005-11-28 Warner-Lambert Company Pirido(2,3-d)pirimidin-2,7-diaminski inhibitori kinaze
CZ20022929A3 (cs) * 2000-03-06 2003-02-12 Warner-Lambert Company 5-Alkylpyrido[2,3-d]pyrimidinové inhibitory tyrosinových kinas
ES2311532T3 (es) 2000-08-04 2009-02-16 Warner-Lambert Company Llc 2-(4-pirdil)amino-6-dialcoxifenil-pirido(2.3-d)pirimidin-7-onas.
WO2003000011A2 (en) * 2001-06-21 2003-01-03 Ariad Pharmaceuticals, Inc. Novel pyridopyrimidines and uses thereof
AU2002952453A0 (en) * 2002-11-01 2002-11-21 Novogen Research Pty Ltd Aminated isoflavonoid derivatives and uses thereof
US20050009849A1 (en) 2003-01-03 2005-01-13 Veach Darren R. Pyridopyrimidine kinase inhibitors
TW200502236A (en) * 2003-03-28 2005-01-16 Hoffmann La Roche Novel pyrido[2,3-d]pyrimidin-7-carboxylic acid derivatives, their manufacture and use as pharmaceutical agents
WO2005105097A2 (en) 2004-04-28 2005-11-10 Gpc Biotech Ag Pyridopyrimidines for treating inflammatory and other diseases
FR2873118B1 (fr) 2004-07-15 2007-11-23 Sanofi Synthelabo Derives de pyrido-pyrimidine, leur application en therapeutique
FR2887882B1 (fr) * 2005-07-01 2007-09-07 Sanofi Aventis Sa Derives de pyrido[2,3-d] pyrimidine, leur preparation, leur application en therapeutique
FR2896246B1 (fr) 2006-01-13 2008-08-15 Sanofi Aventis Sa Derives de pyrido-pyrimidone, leur preparation, leur application en therapeutique.
US8338435B2 (en) * 2006-07-20 2012-12-25 Gilead Sciences, Inc. Substituted pyrido(3,2-D) pyrimidines and pharmaceutical compositions for treating viral infections

Also Published As

Publication number Publication date
EA200800223A1 (ru) 2008-06-30
DOP2006000145A (es) 2008-01-31
MA29561B1 (fr) 2008-06-02
EA014312B1 (ru) 2010-10-29
US7504406B2 (en) 2009-03-17
DK2020410T3 (en) 2014-03-24
TWI321566B (en) 2010-03-11
PL2020410T3 (pl) 2014-05-30
BRPI0613020A2 (pt) 2010-12-14
DE602006005246D1 (de) 2009-04-02
US8008310B2 (en) 2011-08-30
PT2020410E (pt) 2014-03-20
ZA200711032B (en) 2009-04-29
CN102260258A (zh) 2011-11-30
RS53211B (en) 2014-08-29
US20090163522A1 (en) 2009-06-25
PT1902054E (pt) 2009-04-22
ME01813B (me) 2014-09-20
JP2008544975A (ja) 2008-12-11
SI2020410T1 (sl) 2014-04-30
PA8684801A1 (es) 2007-01-17
CN101213196B (zh) 2011-09-07
CA2610794A1 (fr) 2007-01-11
US20080176874A1 (en) 2008-07-24
CY1114989T1 (el) 2016-12-14
TNSN07440A1 (en) 2009-03-17
EP1902054B1 (fr) 2009-02-18
FR2887882B1 (fr) 2007-09-07
EP2020410B1 (fr) 2013-12-18
ATE423119T1 (de) 2009-03-15
IL187900A0 (en) 2008-03-20
AR054812A1 (es) 2007-07-18
ES2450067T3 (es) 2014-03-21
KR20080021714A (ko) 2008-03-07
PL1902054T3 (pl) 2009-07-31
JP4472009B2 (ja) 2010-06-02
HRP20140246T1 (hr) 2014-06-20
CA2610794C (fr) 2012-02-21
WO2007003765A1 (fr) 2007-01-11
SI1902054T1 (sl) 2009-06-30
UY29645A1 (es) 2007-01-31
EP2020410A1 (fr) 2009-02-04
ECSP078011A (es) 2008-01-23
NZ564072A (en) 2012-02-24
AU2006264801B2 (en) 2012-05-10
CN102260258B (zh) 2015-01-07
CN101213196A (zh) 2008-07-02
HK1122797A1 (en) 2009-05-29
NO20080418L (no) 2008-03-28
MX2007016239A (es) 2008-03-06
MY143089A (en) 2011-03-15
KR101298344B1 (ko) 2013-08-20
HRP20090236T1 (en) 2009-05-31
CY1110457T1 (el) 2015-04-29
EP1902054A1 (fr) 2008-03-26
AU2006264801A1 (en) 2007-01-11
RS50781B (sr) 2010-08-31
JO2550B1 (en) 2010-09-05
UA92021C2 (ru) 2010-09-27
TW200745102A (en) 2007-12-16
PE20070139A1 (es) 2007-03-07
FR2887882A1 (fr) 2007-01-05
ES2322101T3 (es) 2009-06-16
DK1902054T3 (da) 2009-06-15

Similar Documents

Publication Publication Date Title
CR9568A (es) DERIVADOS DE PIRIDO[2,3-d]PIRIMIDINA, SU PREPARACION, SU APLICACION EN TERAPEUTICA
CY1120257T1 (el) ΠΥΡΡΟΛΟ[2,3b]ΠΥΡΙΔΙΝ-4-ΥΛΑΜΙΝΕΣ ΚΑΙ ΠΥΡΡΟΛΟ[2,3b]ΠΥΡΙΜΙΔΙΝ-4-ΥΛΑΜΙΝΕΣ ΩΣ ΑΝΑΣΤΟΛΕΙΣ ΚΙΝΑΣΩΝ JANUS
UY29439A1 (es) Nuevos compuestos
ECSP11010904A (es) Compuestos de pirrolo[2,3-d]pirimidina
DOP2012000080A (es) Compuestos de pirrolo[2,3-d]pirimidina
CL2008001745A1 (es) Compuestos derivados de imidazo[1,2-a]pirazina; composición farmacéutica; y uso de los compuestos como inhibidores de la proteína quinasa en el tratamiento del cáncer.
MX2011012353A (es) Derivados de n-(hetero)aril-pirrolidina de pirazol-4-il-pirrolo[2, 3-d]pirimidinas y pirrol-3-il-pirrolo[2,3-d]pirimidinas como inhibidores de la cinasa janus.
CY1116574T1 (el) Ετεροαρυλο υποκατεστημενες πυρρολο[2,3-β]πυριδινες και πυρρολο[2,3-β]πυριμιδινες ως αναστολεις κινασης janus
MX370814B (es) Pirazolo[3,4-d]pirimidinas sustituidas y usos de las mismas.
UY30057A1 (es) Pirimidinas sustituidas con sulfoximinas, procesos para su producción y uso de las mismas como fármacos
MXPA03001511A (es) Imidazol-5-il-2-amino-pirimidinas como agentes para la inhibicion de la proliferacion celular.
CL2011000489A1 (es) Compuestos derivados de pirimido[5,4-d]pirimidina, los cuales actuan como inhibidores de tirosina-quinasas; y composiciones farmaceuticas que los comprenden, utiles en el tratamiento de enfermedades que se caracterizan por una proliferacion celular excesiva o anomala
MX2010004576A (es) Derivados de pirimidina novedosos.
BRPI0923786C1 (pt) compostos 5,6-dihidro-6-fenilbenzo(f) isoquinolina-2- amina substituidos e composições farmacêuticas compreendendo ditos compostos
NZ596571A (en) Pyrazolopyrimidines and related heterocycles as kinase inhibitors
CL2007001710A1 (es) Compuestos derivados de amino-pirazolopiridina sustituidos; metodo de preparacion; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como tumores, artritis reumatoide, enfermedades de crecimiento vascular desregulado, entre otras.
SV2006002283A (es) Formulaciones
CL2011000119A1 (es) Compuestos derivados de triazolo[4,3-a]piridina; procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer.
CL2009000512A1 (es) Compuestos heterociclicos sustituidos derivados de imidazo[4,5-d]piridazina, imidazo[4,5-c]piridazina, imidazo[4,5d]pirimidina, entre otros; composicion farmaceutica que comprende a dichos comppuestos; y uso para tratar el virus de la hepatitis c.
ZA200803420B (en) Formulations comprising jorumycin-, reni eramycin-, safracin-related or saframycin-related compounds for treating proliferative diseases
DK1899343T3 (da) Halogenerede pyrazolo[1,5-A]pyrimidiner, fremgangsmåder, anvendelser som GABA-A-receptorligand, sammensætninger og mellemprodukter
ZA201000581B (en) 1,2,3,4-tetrahydropyrrolo[1,2-a]pyrazine-6-carboxamide and 2,3,4,5-tetrahydropyrrolo[1,2-a][1,4]-diazepine-7-carboxamide derivatives,preparation and therapeutic use thereof
AR056279A1 (es) Derivados de aril 1,4- pirazina sustituidos, composicion farmaceutica y un metodo in vitro
UY29109A1 (es) Derivados de alquiliden-tetrahidronaftaleno, procedimiento para su preparacion y su uso como antiinflamatorios
DK2059521T3 (da) Pyrazolo[1,5-A]pyrimidiner, fremgangsmåder, anvendelse og sammensætninger